share_log

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Goodman Tony

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities

Adial Pharmaceuticals | 4：持股变动声明
美股sec公告 ·  03/27 18:10
Moomoo AI 已提取核心信息
Tony Goodman, the Chief Operating Officer of Adial Pharmaceuticals, Inc. (ADIL), was reported to have engaged in a transaction involving the company's stock on March 25, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of the shares, were not disclosed in the announcement. The number of shares held by Goodman after the transaction was also not provided. This information is crucial for investors to understand the insider activity within Adial Pharmaceuticals and may influence their investment decisions.
Tony Goodman, the Chief Operating Officer of Adial Pharmaceuticals, Inc. (ADIL), was reported to have engaged in a transaction involving the company's stock on March 25, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of the shares, were not disclosed in the announcement. The number of shares held by Goodman after the transaction was also not provided. This information is crucial for investors to understand the insider activity within Adial Pharmaceuticals and may influence their investment decisions.
据报道，阿迪尔制药公司（ADIL）首席运营官托尼·古德曼于2024年3月25日参与了一项涉及该公司股票的交易。公告中未披露该交易的具体细节，包括股票数量、股票性质、交易价格和股票总价值。也没有提供交易后古德曼持有的股票数量。这些信息对于投资者了解Adial Pharmicals内部活动至关重要，并可能影响他们的投资决策。
据报道，阿迪尔制药公司（ADIL）首席运营官托尼·古德曼于2024年3月25日参与了一项涉及该公司股票的交易。公告中未披露该交易的具体细节，包括股票数量、股票性质、交易价格和股票总价值。也没有提供交易后古德曼持有的股票数量。这些信息对于投资者了解Adial Pharmicals内部活动至关重要，并可能影响他们的投资决策。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息